SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Community discussion is focused on Palantir's strong earnings beat, exceptional U.S. commercial revenue growth, and robust forward guidance, fueling bullish sentiment about its AI market position while bears continue to highlight extreme valuation concerns.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following its announcement of acquiring two new strategic sites, which more than doubles its total infrastructure capacity to 2.8 GW. The community is buzzing with bullish sentiment, viewing this as a transformative move that significantly strengthens its position as a major AI and high-performance computing provider and could trigger a short squeeze.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

A historic collapse in natural gas prices, driven by rapidly warming weather forecasts and recovering production from freeze-offs, has sent BOIL plummeting, prompting community debate on whether the "widow maker" ETF will see a short-term rebound amidst ongoing bearish sentiment.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending as its stock experiences a significant sell-off despite reporting a strong quarter with accelerating growth and customer acquisition, leading to widespread community frustration and claims of market manipulation. Investors are actively debating whether this is a "buy the dip" opportunity given historically oversold conditions and potential S&P 500 inclusion in March, or if recent equity offerings and analyst downgrades signal further downside.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as hyperscalers like Microsoft and Meta signal unprecedented demand for AI infrastructure, with investors looking to upcoming earnings for further catalysts amidst community debate over recent stock volatility and long-term potential.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne (TER) is trending after reporting strong Q4 earnings and issuing Q1 guidance significantly above analyst expectations, driven by robust AI-related demand in compute and chip testing. The community is actively discussing the impressive beat and notable after-hours price surge, with many anticipating continued momentum from the expanding AI sector.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is a focal point ahead of its Q4 earnings report, with investors deeply divided: some anticipate a strong rebound from recent lows driven by potential ad monetization improvements, while others express frustration over continuous stock declines and CEO performance, amidst broader concerns about global social media regulations.

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Perspective Therapeutics (CATX) is trending with high volume after an announced $175 million equity offering, polarizing the community between those who see it as a strategic move attracting institutional interest and extending cash runway, and others concerned about dilution. This comes amidst speculation around a potential buyout and reduced competition in the radiopharmaceutical sector, following Sanofi's deprioritization of a competing therapy.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is trending amid community buzz following the recent FDA approval of an updated Afrezza label for clearer dosing guidance, with widespread debate on whether this and the Afrezza launch in India will overcome historical challenges and high short interest to drive significant sales, alongside ongoing pipeline catalysts.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending after a sharp sell-off, primarily driven by the broader crypto market downturn and concerns over prediction market seasonality, creating a divided community of investors. Many are seizing the perceived oversold opportunity, bolstered by recent bullish analyst upgrades and Cathie Wood's ARK increasing its stake, while others anticipate continued downward pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research

Zacks Research cut shares of Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday...

New Strong Sell Stocks for January 20th

DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports...

Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position

Acorn Capital Advisors LLC boosted its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 19.9% in the second quarter, according to the company in its most recent Form 13F filing...

Brookline Capital Management Weighs in on CADL Q4 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings estimates for Candel Therapeutics in a report issued on Sunday...

Stephens Reaffirms Overweight Rating for Candel Therapeutics (NASDAQ:CADL)

Stephens reaffirmed an "overweight" rating and set a $15.00 price target on shares of Candel Therapeutics in a research note on Monday...

Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat...

<ul class="summary-bullets"><li>Traders await the September Core PCE report, the Fed’s preferred inflation gauge. Market odds still overwhelmingly point to a rate cut next week.</li><li>Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.</li><li>Retail chatter is driving sharp moves in names like SMX, SoFi, Rubrik, and Praxis.</li></ul>U.S. stock futures are trading modestly higher in early trade on Friday, suggesting a positive start for Wall Street. It follows a mixed session yesterday and is primarily driven by stronger anticipation of a Federal Reserve rate cut at the upcoming December FOMC meeting.Among crucial economic data to monitor, the&nbsp;September Core PCE Price Index data releases today, which is considered the Fed's preferred inflation gauge.&nbsp;According to the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">&nbsp;CME FedWatch tool</a>, the market is now pricing in an 87% chance of an interest rate cut next Wednesday, down from 90% a day earlier.As of 2:45 a.m. ET on Thursday, the Nasdaq 100 futures and S&amp;P 500 futures were up 0.4% and 0.2%, while the Dow futures and the Russell 2000 futures were flattish with a positive bias. On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and that toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘bearish’ early Thursday.&nbsp;Stocks On Trending Watchlist&nbsp;Netflix (NFLX) is reportedly winning the bidding war for a major WBD deal, outbidding Paramount (PSKY). Keep an eye on Warner Bros.Discovery (WBD) stock as well.&nbsp;Security Matters (SMX) is the top-trending stock on Stocktwits as retail chatter rises over a potential short squeeze. Retail sentiment is trending in ‘extremely high’ territory. In other news, the company approved key proposals and re-elected directors at its annual general meeting in Dublin.SoFi Technologies (SOFI) slipped&nbsp;over 6% in after-hours trading after an equity offering. It is looking to raise $1.5 billion in a share sale as it diversifies beyond lending into other products.Apple (AAPL)&nbsp;remains on retail radar on news of executive transitions focused on AI and ongoing regulatory reviews of its App Store rules in Europe.Rubrik (RBRK) saw a significant after-hours pop after a surprise profit and stronger guidance tied to AI demand.Samsara (IOT)&nbsp;has gained retail traction post a strong Q3 earnings print.&nbsp;Wells Fargo raised the firm's price target to $52 from $50 and keeps an Overweight rating on the shares, while JPMorgan raised the firm's price target to $48 from $46 and keeps a Neutral rating.Candel Therapeutics (CADL) is on retail radar on Friday. The company is scheduled to hold&nbsp;an R&amp;D event at 11:00 am ET to detail the BLA roadmap for prostate cancer drug CAN-2409.Praxis Precision Medicines (PRAX)&nbsp;is also inching higher on Stocktwit’s trending list after positive results from the EMBOLD relutrigine study. The company also&nbsp;confirmed it has an upcoming meeting with the FDA to discuss the results and the path forward for a New Drug Application (NDA).&nbsp;Other stocks to keep on the watchlist post their earnings release in after-hours are&nbsp;Domo (DOMO), HP Enterprise (HPE), SentinelOne (S), and DocuSign (DOCU).Key Catalysts To Watch Out ForOn the economic front, investors will be watching for data on inflation and consumer health ahead of the Federal Reserve's final policy meeting of the year.<ul><li>September Core PCE Price Index (10:00 am ET)</li><li>September Personal Income/Spending Data (10:00 am ET)</li><li>December Michigan Consumer Sentiment (10:00 am ET)</li><li>Consumer Credit Change (3:00 pm ET)</li></ul>And on the earnings front, investors will be watching for Victoria’s Secret ($VSCO) pre-market, among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.

Equity

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.


Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $24.00

Citigroup reduced their price target on shares of Candel Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday...

Candel Therapeutics (NASDAQ:CADL) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.24	--	--	N/A
Q3 '25	-$0.19	-$0.21	-13.40%	MISSED
Q2 '25	-$0.16	-$0.09	45.02%	BEAT
Q1 '25	-$0.37	$0.13	134.70%	BEAT
Q4 '24	-$0.23	-$0.40	-75.74%	MISSED

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CADL News

CADLCandel Therapeutics Inc